Sustained Efficacy of Eptinezumab in Participants with Migraine for Whom Prior Preventive Treatments Failed and Who Self-reported Psychiatric Comorbidities: Post Hoc Analysis of the Placebo-controlled DELIVER Trial
The central aim is to evaluate the sustained efficacy of eptinezumab in migraine patients with a history of treatment failure and psychiatric comorbidities.
Post hoc analysis of data from the DELIVER trial
Included participants with prior preventive treatment failures
Focused on those with self-reported psychiatric comorbidities
Eptinezumab showed sustained efficacy in reducing migraine frequency
Participants reported fewer migraine days compared to placebo
Improvement was consistent among those with psychiatric conditions
Sustained Efficacy of Eptinezumab in Participants with Migraine for Whom Prior Preventive Treatments Failed and Who Self-reported Psychiatric Comorbidities: Post Hoc Analysis of the Placebo-controlled DELIVER Trial | Synapse
Also Consider
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: